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Acute Myeloid Leukemia: The
Race to Diagnosis and
Treatment!
Leila Khaddour, MD, Vijaya Donthireddy, MD, Vrushali Dabak, MD,
Hematology and Oncology Department
Henry Ford Hospital

Introduction
Acute myeloid leukemia (AML) is the most common acute
leukemia affecting adults and one of the hematologic
emergencies that require prompt treatment.
AML is typically categorized based on combinations of mutations
and/or altered expression of certain genes

FLT3 mutation is associated poor prognosis and early relapse in
AML. Midostaurin is a multi-kinase inhibitor, when added to
induction 7+3 chemotherapy starting at day 8-21, improves the
response rate and disease-free survival.
Genetic profiling should be performed on newly diagnosed
patients with AML. Particularly it is important to get the result of
FLT3 mutation before day 8 of induction.

Purpose
 Evaluate our institution efficiency obtaining the appropriate
molecular studies in AML cases at the time of diagnosis.
 Time is very sensitive in the management of acute myeloid
leukemia. Induction chemotherapy should be administered
once morphologic diagnosis is made and usually before
the genetic testing results are available
 It requires high collaboration between the hematologist,
pathologist and laboratory staff.
 Once molecular studies are available, the need for targeted
therapy will be determined. Next generation sequencing (NGS)
is fast and comprehensive method in molecular analysis

Methods
• The electronic medical records were reviewed for all AML cases
diagnosed between January 2016 and December 2018.
• Quality measures were defined:
1.

2.
3.
4.

Average duration between bone marrow biopsy and the morphology
results.
Average duration between bone marrow biopsy and date of molecular
order.
Average duration between molecular order and available results.
Average duration between induction date
and the administering Midostaurin if needed for FLT3 mutated cases.

RESULTS
Between January 2016 and December
2018, 86 AML cases were diagnosed and
treated in out institution. 76% of cases
were diagnosed in the hospital while in
24% diagnosis was in bone marrow biopsy
obtained in the clinic.
All patients were admitted to the hospital.
Morphology results were reported on
average of 3 and 4.2 days in the inpatient
and outpatient setting respectively

Type of
Molecular
Study

 Molecular studies were obtained in 65 cases
• NGS panel in 19 cases• De-novo AML in 22 cases
• Custom in 24 cases

Molecular Study Results Time Range

FLT3
Mutation
Positive

 The average time between induction and FLT3 mutation results is 12.38
days
 The average delay in administering the target therapy(midostaurin) is
4.38 days

Discussion
 Our institution experience has improved in the past 3 years
increasing the rate of ordering molecular studies for newly diagnosed
AML.
 NGS-54 gene panel is an institutional comprehensive panel includes
all gene of interest and includes FLT3 mutation. There has been an
increasing rate in ordering this panel; 9 cases in 2017 to 17 cases in
2018
 FLT3 mutation analysis was included in a total of 51 patients over 3
years. However, in 2018, It was included in
29/31 cases which correlates with the clinical use of FLT3 inhibitor

Discussion
 In cases with FLT3 mutation, there is an average 4.38-day delay in
administering targeted therapy due to the delay ordering and getting
the results in appropriate time manner.
 We suggested the following changes:
1. Standardize the order by obtaining NGS-54 gene panel on all Leukemia
cases at the time of obtaining the bone marrow biopsy
2. Ongoing discussion between the hematology department
and pathology department to improve the communication and ordering
pathways
2. Address the efficacy of these measures in new AML cases diagnosed in 2019.

Conslusion

 Obtaining the genetic profiling is very
important prognostic and therapeutic measure in newly
diagnosed AML. The presence of FLT3 mutation convey poor
prognosis. FLT3 inhibitor, Midostaurin, when added on Day 8 of
induction improves the outcomes.
 In our institution experience, there is an average delay of 4.38 days
in administering midostaurin in FLT3 mutated AML cases.
 We believe that standardizing the ordering
process with obtaining NGS panel on all new leukemia cases
will improve and expedite getting the results in appropriate manner

